Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis

By C. Corpechot, L. Abenavoli, N. Rabahi, Y. Chrétien, T. Andréani, C. Johanet, O. Chazouilleres, R. Poupon. Hepatology, 2008

638 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. (2016, background): “(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2018, methodology): “(148) Biochemical response should be assessed after 1 year of treatment with UDCA using one of many published criteria shown in Table 1.(60,77-79,149-152) When one of these binary definitions for response to UDCA is used, up to 40% of PBC patients will have an inadequate response to treatment.”
Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. (2021, background): “In primary biliary cholangitis (PBC) similarly to other chronic liver diseases, advanced histological stages are associated with poor prognosis [180-185]; fibrosis stage was”
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017, positive): “Advanced histological stages are consistently associated with a poor prognosis in PBC [93,94,47,63,95].”
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. (2009, neutral): “51%) ten year transplant-free survival [28].”